KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
MDM2 Inhibition with Alrizomadlin (APG-115) in TP53 wild-type salivary gland cancers: a phase I clinical trial. PMID 41857036 · Nat Commun · 2026-Mar-19 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of an early warning system on the outcome of patients with haematological malignancies receiving high-dose chemotherapy with or without haematopoietic cell transplantation: a protocol of the ALHERT cluster randomised trial. PMID 41856593 · BMJ Open · 2026-Mar-19 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-term outcomes of eribulin‑based neoadjuvant chemotherapy for triple‑negative breast cancer patients stratified by homologous recombination deficiency status: results of the randomized JBCRG-22 study. PMID 41854792 · Breast Cancer Res Treat · 2026-Mar-19 The record is an original report of a randomized trial in oncology with time-to-event endpoints and drug interventions. However, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (abstract, publication types, mesh terms). The deterministic review correctly identifies the phase evidence as unclear. Therefore, eligibility cannot be confirmed.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
"Having surgery is necessary" - a qualitative analysis of the experiences of frail older adults treated with, and recovering from colorectal cancer surgery. PMID 41845272 · BMC Geriatr · 2026-Mar-17 This is a qualitative analysis of patient experiences from the control group of a randomized trial. It does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) and lacks a drug-containing intervention. The publication type is 'Journal Article' with 'Randomized Controlled Trial' but the content is qualitative, not a primary/secondary efficacy result.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Integrated psychological resilience and nutritional support improves sleep, emotional wellbeing, inflammation, and clinical recovery in colon cancer: a randomized controlled trial. PMID 41841224 · Psychol Health Med · 2026-Mar-17 The study is an oncology RCT with time-to-event endpoints, but it fails the drug intervention criterion (intervention is non-drug). The phase is also not definitively established as Phase III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Fc-enhanced anti-CTLA-4 targets Tregs to augment androgen deprivation in high-risk prostate cancer: A randomized phase I trial. PMID 41759531 · Cell Rep Med · 2026-Mar-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The effects of a smoking cessation intervention on mortality after a 32.5-year follow-up period: a randomized clinical trial. PMID 41164942 · Am J Epidemiol · 2026-Mar-17 Study is a randomized clinical trial with time-to-event mortality endpoints, but it is a smoking cessation intervention trial (non-drug) and does not provide evidence of being a Phase III/IIIb or Phase II/III oncology trial. The primary intervention is behavioral (smoking cessation program) with bronchodilator/placebo arms, but the drug component (bronchodilator) is not the primary intervention and the trial is not focused on a drug-containing oncology treatment.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. PMID 41128642 · J Clin Endocrinol Metab · 2026-Mar-17 The study is a Phase III randomized trial of a drug for acromegaly, which is not a human malignant neoplasm. The primary efficacy endpoint is a biochemical response (IGF-I normalization), not a time-to-event endpoint like OS, PFS, or DFS, and there is no indication of Kaplan-Meier analysis or hazard ratios for survival/time-to-event data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase II Trial of an Extended-Release siRNA Implant Targeting KRASG12D/V in Locally Advanced Pancreatic Cancer. PMID 41528981 · Clin Cancer Res · 2026-Mar-16 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Valued Living intervention to increase advance care planning and well-being in depressed and anxious adults with advanced cancer: Randomized trial in community oncology clinics. PMID 41848105 · Cancer · 2026-Mar-15 The study is a randomized trial in oncology patients but fails key eligibility criteria: it is not explicitly a Phase III trial, lacks a time-to-event primary efficacy endpoint (OS/PFS/etc.), and does not involve a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eligibility criteria in phase 3 randomized controlled trials in metastatic non-small cell lung cancer. PMID 41838447 · Cancer · 2026-Mar-15 This is a meta-analysis of eligibility criteria across multiple phase 3 RCTs, not an original report of a single trial's efficacy results. It lacks a primary/key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized phase II trial of gemcitabine, nab-paclitaxel, cisplatin with or without a medically supervised ketogenic diet for patients with metastatic pancreatic cancer. PMID 41817106 · Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Parotid-Sparing Versus Conventional Whole Brain Radiation Therapy: A Multi-Institutional Randomized Clinical Trial. PMID 41161645 · Int J Radiat Oncol Biol Phys · 2026-Mar-15 The study is a randomized trial in oncology with original results, but it does not meet all required criteria: it lacks a drug-containing intervention (it compares radiotherapy techniques), it has no time-to-event efficacy endpoint (the primary endpoint is xerostomia score), and the phase is not explicitly stated as Phase III/IIIb or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HEBERSaVax immunotherapy combined with first-line chemotherapy in advanced ovarian cancer: Phase II CENTAURO-4 trial results. PMID 41099583 · Int J Cancer · 2026-Mar-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
[Comparison of the efficacy and safety of venetoclax plus azacitidine versus D-CAG regimen in the treatment of elderly patients with relapsed or refractory acute myeloid leukemia]. PMID 41991313 · Zhonghua Xue Ye Xue Za Zhi · 2026-Mar-14 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Pimicotinib versus placebo for tenosynovial giant cell tumour (MANEUVER): an international, randomised, placebo-controlled, phase 3 trial. PMID 41796601 · Lancet · 2026-Mar-14 The trial meets criteria for oncology, human, randomized, Phase III, drug intervention, and original result, but the primary efficacy endpoint is ORR, which is not a time-to-event endpoint as required. No time-to-event signal (Kaplan-Meier, HR, or time-to-event outcome) is identified in the abstract.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Analysis of One Versus Three Fractions of Stereotactic Body Radiation Therapy for Peripheral Stage I to II Non-Small Cell Lung Cancer: A Randomized, Multi-Institution, Phase 2 Trial. PMID 41833909 · Int J Radiat Oncol Biol Phys · 2026-Mar-13 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Associations between tumor immune response and prognosis in node-negative breast cancer patients in the randomized DBCG HYPO trial. PMID 41826895 · BMC Cancer · 2026-Mar-13 The study is a randomized trial in oncology reporting a time-to-event endpoint, but it investigates radiotherapy fractionation schedules, not a drug-containing intervention. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata. The primary focus is a biomarker/prognostic analysis, not the reporting of a drug's efficacy in a definitive trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Validation of the Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) in patients with multiple myeloma who were enrolled in the CARTITUDE-4 trial. PMID 41824255 · J Patient Rep Outcomes · 2026-Mar-13 The study is part of a Phase III randomized trial (CARTITUDE-4) evaluating a drug intervention (ciltacabtagene autoleucel) in oncology (multiple myeloma). However, this specific abstract reports validation of a patient-reported outcome instrument (MySIm-Q) using trial data, not a time-to-event efficacy outcome (OS, PFS, DFS, etc.) or Kaplan-Meier/HR analysis. Therefore, it does not meet the time-to-event efficacy endpoint criterion for inclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Clinical Trial Protocol for the Apa/Enza-short Study: A Randomized Nationwide Study of Shortened 12-Month Duration of Androgen Receptor Signaling Agent in Combination With Androgen Deprivation Therapy in Patients With Metastatic Low-volume Castration-sensitive Prostate Cancer. PMID 41826123 · Eur Urol Focus · 2026-Mar-12 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Quality of Life in Patients With p16+ Oropharyngeal Cancer Receiving Accelerated Radiation Therapy With Either Cisplatin or Cetuximab in the NRG/RTOG 1016 Randomized Controlled Trial. PMID 41825810 · Int J Radiat Oncol Biol Phys · 2026-Mar-11 The report is a secondary analysis of a Phase III randomized trial, but it focuses on quality-of-life outcomes, not a time-to-event efficacy endpoint required for the cohort.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysis. PMID 41702246 · Eur J Cancer · 2026-Mar-11 The record describes an updated report of a randomized Phase III trial in resectable stage-III NSCLC, with a drug-containing intervention and primary time-to-event endpoint (OS). The abstract confirms randomized design, drug intervention, and OS results with KM analysis. Phase is confirmed as definitive (Phase III) from the reference to the original trial (Eberhardt et al, J Clin Oncol 2015).
B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Use of concomitant G-CSF in maintaining efficacious dose and safe delivery of docetaxel in combination with darolutamide in ARASENS: A phase III study. PMID 41655462 · Eur J Cancer · 2026-Mar-11 This is a formal-result report from a Phase III randomized trial (ARASENS) but presents a secondary safety and dose-intensity analysis. It does not contain a primary or key secondary time-to-event efficacy endpoint (OS, PFS, etc.) as required for inclusion in the Kaplan-Meier digitization cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The Effect of Motivational Interviewing Based on the COM-B Model on Women's Cervical Cancer Health Beliefs and Participation in Screening: A Single-Blind Randomized Controlled Trial. PMID 41812047 · Cancer Nurs · 2026-Mar-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Erdafitinib or Erdafitinib Plus Cetrelimab for Patients With Metastatic Urothelial Carcinoma and FGFR Alterations: Final Results From the Phase II NORSE Study. PMID 41538748 · J Clin Oncol · 2026-Mar-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Atezolizumab and motixafortide, cobimetinib or simlukafusp alfa in pretreated advanced pancreatic cancer: phase I/IIb MORPHEUS-PDAC umbrella study. PMID 41741368 · Oncologist · 2026-Mar-09 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term survival outcomes after biomarker-guided thromboprophylaxis in cancer: extended follow-up of the TARGET-TP randomised trial. PMID 41795841 · J Natl Cancer Inst · 2026-Mar-07 While the record meets many inclusion criteria (oncology, human, randomized, time-to-event, drug intervention, original result), the specific trial phase (Phase III/IIIb or Phase II/III) is not established in the provided metadata. The deterministic review note explicitly flags that phase evidence is unclear. Without confirmation of a definitive phase, eligibility cannot be set to true.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
DNA Repair gene alterations and efficacy from gemcitabine and nab-paclitaxel with/without durvalumab and tremelimumab in metastatic pancreatic ductal adenocarcinoma. PMID 41794844 · Nat Commun · 2026-Mar-07 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Intravenous lidocaine reduces systemic inflammation but not myocardial injury following thoracic surgery for lung cancer: a randomized controlled trial. PMID 41794665 · BMC Anesthesiol · 2026-Mar-07 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparative effectiveness of CDK4/6 inhibitors in metastatic breast cancer: using the target trial emulation framework to investigate overall survival in routine care. PMID 41793559 · Breast Cancer Res Treat · 2026-Mar-07 The study is an observational comparative effectiveness analysis using a target trial emulation framework on real-world data, not a report of an original Phase III/IIIb or Phase II/III randomized controlled trial with a drug intervention. It does not meet the criteria for a primary or secondary report of a definitive randomized trial.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Kidney-Tonifying, Phlegm-Resolving, and Blood Stasis-Removing Therapy for Multiple Myeloma: Protocol for a Randomized Controlled Trial on Epigenetic and Immune Modulation. PMID 41813432 · JMIR Res Protoc · 2026-Mar-05 This is a protocol for a randomized trial in multiple myeloma, but it is not Phase III/IIIb or Phase II/III, and it lacks primary or secondary time-to-event efficacy endpoints (e.g., OS, PFS, DFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Thermal ablation versus hepatectomy for solitary colorectal liver metastases up to 5 cm: a multicenter target trial emulation on safety, efficacy, and cost-effectiveness. PMID 41787469 · BMC Med · 2026-Mar-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety of extending dosing intervals of denosumab in adults with solid cancer and bone metastasis: a review. PMID 41785076 · Br J Nurs · 2026-Mar-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Heart failure therapy in patients with advanced cancer receiving specialized palliative care (EMPATICC trial). PMID 40884070 · Eur Heart J · 2026-Mar-05 The trial is a randomized, double-blind, placebo-controlled study in advanced cancer patients, but the primary endpoint is a composite of functional/well-being measures, not a time-to-event efficacy endpoint. Mortality is mentioned as a secondary safety measure, not as a primary or key secondary time-to-event endpoint for efficacy analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Androgen deprivation, androgen receptor-targeted vaccination, and nivolumab in patients with high-risk localized prostate cancer. PMID 41781018 · J Immunother Cancer · 2026-Mar-04 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Long-term follow-up of S0221, comparing alternative dose-schedules of anthracycline and taxane therapy in early breast cancer. PMID 41832961 · JNCI Cancer Spectr · 2026-Mar-03 The record describes a randomized trial with drug intervention and time-to-event endpoints. However, the formal trial phase (Phase III, IIIb, or II/III) is not explicitly stated in the provided metadata (title, abstract, publication types, or MeSH). The deterministic review also flagged 'phase3_evidence_unclear'. Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Sintilimab, pegaspargase, and anlotinib as induction therapy for advanced-stage NKTCL: a multicenter phase II study. PMID 41774854 · Blood Adv · 2026-Mar-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effects of exercise and diet in patients with incurable gastroesophageal cancer: the RADICES study. PMID 41592243 · JNCI Cancer Spectr · 2026-Mar-03 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Significant Incidental Findings in the National Lung Screening Trial and Diagnosis of Extrapulmonary Cancer. PMID 41915394 · JAMA Netw Open · 2026-Mar-02 The record is an original analysis from a large randomized trial (NLST). However, it is not eligible because it is a screening/diagnostic study, not a therapeutic trial. It lacks a drug-containing intervention and a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) for a malignant neoplasm.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. PMID 41915391 · JAMA Netw Open · 2026-Mar-02 The record reports a randomized clinical trial in oncology with primary time-to-event endpoints (OS, PFS) and a drug-containing intervention. However, the trial phase (Phase III/IIIb or Phase II/III) is not explicitly stated in the provided metadata, making it impossible to confirm eligibility under the strict criterion requiring explicit phase evidence.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Smoking Cessation Among Survivors of Cervical Intraepithelial Neoplasia or Cervical Cancer. PMID 41817524 · JAMA Netw Open · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Sivelestat and Incidence of Acute Respiratory Distress Syndrome After Cardiovascular Surgery: A Randomized Clinical Trial. PMID 41811317 · JAMA Netw Open · 2026-Mar-02 The study is a randomized controlled trial of sivelestat vs placebo in cardiovascular surgery patients, reporting on ARDS incidence and 90-day mortality. While it includes a time-to-event outcome (mortality), it is not an oncology study (ARDS is not a human malignant neoplasm). The trial is not identified as Phase III/IIIb or a definitive oncologic trial. Therefore, it does not meet the core eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized Trial Links Time of Day to Immunotherapy Success. PMID 41632563 · Cancer Discov · 2026-Mar-02 The record is a news article reporting on a randomized trial, but the abstract lacks explicit details on the trial phase, a specific time-to-event primary/key secondary endpoint, or statistical results like Kaplan-Meier or HR. Therefore, key eligibility criteria cannot be confidently established from the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect Modification by Serum Vitamin A Levels on the Association between Vitamin D and Relapse or Death in Patients with Digestive Tract Cancer. PMID 41524587 · Cancer Epidemiol Biomarkers Prev · 2026-Mar-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
ESR1 Mutation in Endocrine Treatment-Naïve Endometrial Cancer: Prevalence, Characteristics, and Prognostic Implications, Results from the UTOLA Phase II GINECO Trial. PMID 41504649 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Deep Learning-Derived Sarcopenia Marker Predicts Benefit from Anti-EGFR Therapy in Patients with RAS Wild-type Metastatic Colorectal Cancer. PMID 41489691 · Clin Cancer Res · 2026-Mar-02 The record is from a randomized oncology trial with drug intervention and time-to-event endpoints. However, the explicit phase (III/IIIb or II/III) is not confirmed in the provided metadata. Per instructions, the phase cannot be inferred.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ctDNA Detection with Low-Pass Whole-Genome Bisulfite Sequencing in RAS Wild-Type Metastatic Colorectal Cancer: An Exploratory Objective of the VALENTINO Trial. PMID 41427962 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
KEYLYNK-009: Pembrolizumab plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer after Clinical Benefit from First-Line Pembrolizumab plus Chemotherapy. PMID 41405563 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Neoadjuvant Abemaciclib plus Letrozole Versus Chemotherapy in Patients with HR+/HER2- Highly Proliferative Breast Cancer. PMID 41385615 · Clin Cancer Res · 2026-Mar-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
The 3-Year Results of a 100-Patient Prospective Study of the Safety and Effectiveness of Mia Femtech. PMID 41052824 · Aesthet Surg J · 2026-Mar-02 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -